Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites
NCT01349335
Ascites, Digestive System Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT Number: NCT02163512
Multicentric, observational and prospective study with two groups of treatment: Refractory ascites and non-refractory ascites. All patients should be prescribed beta-adrenergic blockers as primary or secondary profilaxis for variceal bleeding.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
Hospital Universitario Gregorio Marañón, Madrid, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline and after 4 weeks
Time frame: Baseline and after 4 weeks
Time frame: Baseline and after 4 weeks
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Other
Acronym: ALB-BET
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01349335
Ascites, Digestive System Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT01349348
Ascites, Digestive System Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT01359462
Ascites, Digestive System Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07069725
Digestive System Diseases, Fibrosis
Stockholm, Sweden
View Trial Details